Ross Kedl, PhD

Professor of Immunology & Microbiology
University of Colorado

Ross KedlDr. Kedl received his PhD in 1997 in the Department of Laboratory Medicine and Pathology at the University of Minnesota in Minneapolis. Before joining the Faculty at the University of Colorado, Dr. Kedl was at 3M Pharmaceuticals working in their small molecule immune response modifier program. In his three years there, he spearheaded efforts at developing novel vaccine adjuvants, resulting in numerous publications and patents in the area of vaccine technology. Dr. Kedl returned to the academic sector in 2004 by joining the faculty in the Integrated Department of Immunology at the University of Colorado Health Sciences Center and National Jewish Medical Research Center where he continues to pursue the discovery and development of novel and clinically applicable vaccine technology. He is also the founder of a start-up pharmaceutical company, ImmuRx Inc., which focuses on developing therapeutic vaccines against chronic infectious diseases, such as HIV and cancer.

Biography from University of Colorado.

IDIGH Calendar

<<  <  September 2020  >  >>
 Mo  Tu  We  Th  Fr  Sa  Su 
   1  2  3  4  5  6
  7  8  910111213
14151617181920
21222324252627
282930    

Latest IDIGH Publications

  1. Luz, P. M., Torres, T. S., Almeida-Brasil, C. C., Marins, L. M. S., Veloso, V. G., Grinsztejn, B., Cox, J. & Moodie, E. E. M.
    (2020)
    .
    High-Risk Sexual Behavior, Binge Drinking and Use of Stimulants are Key Experiences on the Pathway to High Perceived HIV Risk Among Men Who Have Sex with Men in Brazil
    .
    AIDS and behavior
  2. Sulis, G., Daniels, B., Kwan, A., Gandra, S., Daftary, A., Das, J. & Pai, M.
    (2020)
    .
    Antibiotic overuse in the primary health care setting: a secondary data analysis of standardised patient studies from India, China and Kenya
    .
    BMJ global health
    ,
    vol
    .
    5
  3. Rebeiro, P. F., Jenkins, C. A., Bian, A., Lake, J. E., Bourgi, K., Moore, R. D., Horberg, M. A., Matthews, W. C., Silverberg, M. J., Thorne, J., Mayor, A. M., Lima, V. D., Palella, F. J., Saag, M. S., Althoff, K. N., Gill, M. J., Wong, C., Klein, M. B., Crane, H. M., Marconi, V. C., Shepherd, B. E., Sterling, T. R. & Koethe, J. R.
    (2020)
    .
    Risk of Incident Diabetes Mellitus, Weight Gain, and their Relationships with Integrase Inhibitor-based Initial Antiretroviral Therapy Among Persons with HIV in the US and Canada
    .
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  4. Mendel, A., Ennis, D., Go, E., Bakowsky, V., Baldwin, C., Benseler, S. M., Cabral, D. A., Carette, S., Clements-Baker, M., Clifford, A., Cohen Tervaert, J. W., Cox, G., Dehghan, N., Dipchand, C., Dhindsa, N., Famorca, L., Fifi-Mah, A., Garner, S., Girard, L.-P., Lessard, C., Liang, P., Noone, D., Makhzoum, J.-P., Milman, N., Pineau, C. A., Reich, H. N., Rhéaume, M., Robinson, D. B., Rumsey, D. G., Towheed, T. E., Trudeau, J., Twilt, M., Yacyshyn, E., Yeung, R., Barra, L., Khalidi, N. & Pagnoux, C.
    (2020)
    .
    CanVasc consensus recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitis: 2020 update
    .
    The Journal of rheumatology
  5. Lee, T. C., Wilson, M. G., Lawandi, A. & McDonald, E. G.
    (2020)
    .
    Proton pump inhibitors vs. histamine-2 receptor antagonists likely increase mortality in critical care: an updated meta-analysis
    .
    The American journal of medicine
More publications